Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice

Abstract EN

Introduction.

The aim of this retrospective study was to examine effect of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in daily clinical practice.

Methods.

Patients with histologically or cytologically proven NSCLC (n=84) treated with erlotinib in second-line (n=34), third-line (n=36), and more-line therapy (n=14) were examined for progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of therapy, and adverse effects.

Results.

Median PFS of all lines was 83 days (CI 70.0–96.0), OS was 7 months (CI 4.7–9.3), DCR was 66.2% (CI 55–77%), and 1-year survival rate was 33% (CI 22–43%), with no significant difference between therapy lines.

Median duration of treatment was 76 days (IQR 39–139.5).

Patients with epidermal growth factor receptor mutation (EGFR-M) reached the highest PFS (204 days), as did patients with good performance status (ECOG 0-1: 94 versus ECOG 2-3: 65 days, P=0.035).

Patients with EGFR-M also revealed a DCR of 100%.

The most frequent side effects were rash (69%) and diarrhoea (41%), without any significant difference between therapy lines.

In 24 patients, the treatment dose was reduced and in 18, the therapy was paused.

Conclusion.

Erlotinib works in all therapy lines without any significant differences in efficacy and side effects.